Yisheng Pharmaceutical (002566.SZ) received a notice from the Jilin Drug Administration to lift risk control measures

Zhitong Finance App News, Yisheng Pharmaceutical (002566.SZ) issued an announcement. On July 1, 2026, the company received the “Notice of Adopting Risk Control Measures” issued by the Jilin Drug Administration [2026] T02. After receiving the notice, the company attached great importance to it and immediately set up a special rectification working group to organize management and relevant business departments to list the problems against the notice, sort out and dig deeper into the root causes of the problems item by item, formulate a special rectification plan, and clarify the rectification tasks, responsible subjects, and rectification time frame. The company strictly complies with regulatory requirements to carry out various rectification work, implement rectification of existing defects item by item, improve management systems, strengthen personnel training, and make up for internal control shortcomings. Today, the company received the “Notice of Cancellation of Risk Control Measures” from the Jilin Drug Administration [2026] T02. After on-site inspection, it was confirmed that potential safety hazards have been ruled out and agreed to lift the risk control measures.

After the risk control measures are lifted, the relevant production lines will be organized to resume production in an orderly manner, resume production according to the plan, and guarantee market supply. This incident will not have a significant adverse impact on the company's current operating results.